Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scancell HoldingsFRA:SCP -29.24%23 Cyclically Adjusted PB Ratio is 6.05 as of Jul. 21, 2026, which is 30% above its 10-year median of 4.65. GuruFocus rates FRA:SCP with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 698 Biotechnology companies, Scancell Holdings ranks worse than 84.81% on this metric.
The historical rank and industry rank for Scancell Holdings's Cyclically Adjusted PB Ratio or its related term are showing as below:
FRA:SCP'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.63 Med: 4.65 Max: 11.95
Current: 7.6
During the past 13 years, Scancell Holdings's highest Cyclically Adjusted PB Ratio was 11.95. The lowest was 2.63. And the median was 4.65.
FRA:SCP's Cyclically Adjusted PB Ratio is ranked worse than 84.81% of 698
companies
in the Biotechnology industry
Industry Median: 1.59
vs FRA:SCP: 7.60
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Scancell Holdings's adjusted book value per share data of for the fiscal year that ended in Apr25 was €-0.004. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.02 for the trailing ten years ended in Apr25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Scancell Holdings (FRA:SCP) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Scancell Holdings Cyclically Adjusted PB Ratio Related Terms
Scancell Holdings Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Scancell Holdings's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scancell Holdings Cyclically Adjusted PB Ratio Chart
FRA:SCP vs VRTX, REGN, ALNY: Cyclically Adjusted PB Ratio Comparison
For the Biotechnology subindustry, Scancell Holdings's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scancell Holdings Cyclically Adjusted PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scancell Holdings's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Scancell Holdings's Cyclically Adjusted PB Ratio falls into.
Scancell Holdings Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Scancell Holdings's Cyclically Adjusted PB Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 6.05 mean?
Scancell Holdings (FRA:SCP) has a Cyclically Adjusted PB Ratio of 6.05 as of Jul. 21, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Scancell Holdings and its competitors. This is 30% above median its historical median of 4.65. Over the past decade, Scancell Holdings' Cyclically Adjusted PB Ratio has ranged from 2.63 to 11.95. According to the industry distribution chart, Scancell Holdings ranks #592 out of 698 companies in the Biotechnology industry, placing it in the top 84.8%.
Is Scancell Holdings' Cyclically Adjusted PB Ratio too high?
Scancell Holdings' current Cyclically Adjusted PB Ratio of 6.05 is 30% above median its 10-year median of 4.65. Over the past 10 years, this metric has ranged from a low of 2.63 to a high of 11.95. The Biotechnology industry median Cyclically Adjusted PB Ratio is 1.59. Scancell Holdings' value of 6.05 is 280.5% above this industry median. Based on the distribution chart, Scancell Holdings ranks #592 out of 698 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Scancell Holdings has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' Cyclically Adjusted PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Scancell Holdings ranks #592 out of 698 companies for Cyclically Adjusted PB Ratio. This places Scancell Holdings in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.59. Scancell Holdings' value of 6.05 is 280.5% above this benchmark. Historically, Scancell Holdings' own Cyclically Adjusted PB Ratio has ranged from 2.63 to 11.95 over the past decade. While the company's 10-year median is 4.65 vs. the industry median of 1.59, Scancell Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Biotechnology company?
The median Cyclically Adjusted PB Ratio among Biotechnology companies is 1.59, based on 698 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scancell Holdings's current Cyclically Adjusted PB Ratio of 6.05 is 280.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Scancell Holdings and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PB Ratio is 1.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scancell Holdings's current Cyclically Adjusted PB Ratio is 6.05, which is 30% above median its own 10-year median of 4.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (FRA:SCP) has a current Cyclically Adjusted PB Ratio of 6.05. The current Cyclically Adjusted PB Ratio is 6.05, which is 30% above median its 10-year median of 4.65 and 280.5% above the Biotechnology industry median of 1.59. Scancell Holdings' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Scancell Holdings (FRA:SCP), the current Cyclically Adjusted PB Ratio is 6.05 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
23GF Score
Get the complete analysis for FRA:SCP
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:SCP has been successfully added to your 
